Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues Data reveal engineering approach to significantly reduce kidney accumulation of DARPin-based radiotherapeutic candidates to potentially expand

Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells Preclinical data demonstrated that MP0533 can selectively target and kill both leukemic blast cells and stem cells, while sparing healthy cells

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR :  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents Dose escalation remains ongoing with study recruitment anticipated to complete in 1H 2023 ZURICH-SCHLIEREN, Switzerland and CONCORD,

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022 Initiation of Phase 1 study for MP0533 expected by year end Continued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers;

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR:   Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

Multi-specific DARPin targeting FAP x 4-1BB presently in Phase 1 clinical trial ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company

ZURICH -SCHLIEREN, Switzerland & CONCORD, Mass. , April 26, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:   Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, is